• aaaaaaadjsf [he/him, comrade/them]
    ·
    edit-2
    3 years ago

    It seems that the vaccine being ordered is a new smallpox vaccine that uses the single needle intermuscular injection now, and not the stabby Y thing a few times, got approved in 2019.

    • Neckbeard_Prime [they/them,he/him]
      ·
      3 years ago

      What's your source on the eczema part? The NIH says the opposite, at least in the EU:

      https://www.niaid.nih.gov/diseases-conditions/smallpox-vaccine

      People with weakened immune systems or skin conditions, such as atopic dermatitis, or eczema, are at increased risk for serious side effects from Dryvax and Acam2000. NIAID is pursuing the development of new, safer smallpox vaccines that could be used to protect these groups. One candidate developed by the biotechnology company Bavarian Nordic uses a vaccine platform technology known as Modified Vaccinia Ankara – Bavarian Nordic (MVA-BN). NIAID supported early advanced development work for this important vaccine, with initial efforts largely focused on the liquid formulation. NIAID supported preclinical evaluation through Phase II clinical trials of the investigational vaccine. The trials assessed the vaccine in healthy participants, HIV-positive volunteers, and people with atopic dermatitis or a history of atopic dermatitis. These studies evaluated safety, immunogenicity, duration of protection, and route of vaccination.

      Following promising clinical trials results, MVA-BN was transitioned to the Biomedical Advanced Research and Development Authority (BARDA) for advanced development. In 2013, Canada and the European Union approved the vaccine (under the trade names IMVAMUNE and IMVANEX) for use in the general population, including people with weakened immune systems or atopic dermatitis. As of August 2014, 24 million doses were delivered to the U.S. Strategic National Stockpile (SNS) for use among these groups. BARDA also supported large Phase 3 clinical trials of the vaccine. Based on promising data from these studies, the FDA approved MVA-BN (now called JYNNEOS) in September 2019.

      (Bolded emphasis mine)

      • aaaaaaadjsf [he/him, comrade/them]
        ·
        edit-2
        3 years ago

        That's a much better source, I was trying to decipher the incomprehensible Wikipedia page and the Bavarian Nordic website and PDFs. Which were worded very poorly. Will update my comments, thanks for the correction

          • aaaaaaadjsf [he/him, comrade/them]
            ·
            3 years ago

            The Wikipedia page literally says that the MVA-BN vaccine is unsafe for eczema, which is straight up false, wtf lol.

            Also there's so much redacted stuff on the PDFs on the Bavarian Nordic website it's impossible to read. I found an interesting pdf there about a simulated bioterrorist monkeypox attack on May 15 2022 lmao. Obviously the simulation was made after the June 2021 monkeypox outbreak in Nigeria, and it's just a coincidence, but pretty funny in a :illuminati: way

            • D3FNC [any]
              ·
              3 years ago

              Yeah, like that totally coincidental SARS-COVID-1 simulation they did in fall 2019

            • Neckbeard_Prime [they/them,he/him]
              ·
              edit-2
              3 years ago

              It doesn't, but it does use really fucking confusing wording/nonsensical proximity. Here:

              MVA-BN contains Modified vaccinia Ankara, an attenuated form of the vaccinia virus that does not replicate in human cells and hence does not cause the sometimes serious side effects that are seen with replicating smallpox vaccines (i.e. preparations of unattenuated vaccinia virus). These replicating vaccines use different strains of the vaccinia virus, which all replicate in humans, and are not recommended for people with immune deficiencies and exfoliative skin disorders, such as eczema or atopic dermatitis. Vaccines containing vaccinia viruses were used effectively in the campaign to eradicate smallpox. Because of similarities between vaccinia and the smallpox virus, the antibodies produced against vaccinia have been shown to protect against smallpox. In contrast to replicating smallpox vaccines, which are applied by scarification using a bifurcated needle, MVA-BN is administered by injection via the subcutaneous route.[32]

              Emphasis mine.

              The "These replicating vaccines..." part is referring to Dryvax and ACAM2000 (replicating vaccines). It starts out by stating that MVA-BN is non-replicating, and then goes off on a tangent about replicating variants, which still sounds like it's talking about MVA-BN. The next two sentences are just redundant with the entire article, and shouldn't even be there. That section should have been edited for clarity, because yeah, if you are skimming, it's easy to miss that distinction when three quarters of the fucking paragraph is talking about something that is not applicable to MVA-BN.